Investment
Features
FeesSafety
Academy
More
Pluang+

Compare D R Horton Inc (DHI) vs Novartis AG (NVS) Price & Performance

D R Horton IncTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

D R Horton Inc vs Novartis AG — how do they compare? D R Horton Inc trades at $145.85 (market cap $42.18B), while Novartis AG trades at $152.7 (market cap $295.37B). The key difference: Novartis AG is far larger — about 7× D R Horton Inc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.

DHINVS
Market Cap
$42.18B$295.37B
Sector
Consumer CyclicalHealth
52-Week High
$184.04$168.62
52-Week Low
$132.53$119.31
Enterprise Value
$47.28B$336.69B
Dividend Yield
1.19%3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

D R Horton Inc

DHI trades at $146.66, down 2.93% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.20 versus $3.02 expected. However, revenue and net income have trended lower from 2023 peaks, with 2025 revenue at $34.25B and net income at $3.59B. The company maintains a reasonable valuation with a P/E of 14.37 and recently declared a $0.45 dividend payable in August 2026.

The outlook is mixed; strong execution and cash returns support the stock, but lowered guidance and margin pressure from elevated mortgage rates pose headwinds. Analyst consensus is nearly evenly split between Buy and Hold, with a $153 price target suggesting modest upside. Key risks include persistent demand softness in housing and competitive disruption from new entrants like Boxabl.

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About D R Horton Inc

D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.

Read more on DHI

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS